Scheme | No vaccination | Prophylactic mass | Prophylactic targeted | Reactive mass | Reactive targeted | Ring | Ring and reactive targeted |
---|---|---|---|---|---|---|---|
Baseline (Low/High rate of introductions) | 3 (3–3) | 2 (2–2) | 1 (1–1) | 3 (3–3) | 3 (3–3) | 3 (3–3) | 3 (3–3) |
36 (35–37) | 17 (16–17) | 11 (11–12) | 32 (32–33) | 32 (31–32) | 35 (34–35) | 31 (30–31) | |
Reduced time from reactive vaccination to infective contact (Low/High rate of introductions) | 3 (3–3) | 2 (2–2) | 1 (1–1) | 3 (3–3) | 3 (3–4) | 3 (3–3) | 3 (3–3) |
36 (35–37) | 17 (16–17) | 11 (11–12) | 33 (32–33) | 33 (33–34) | 36 (36–37) | 32 (32–33) | |
Lower Vaccination coverage (Low/High rate of introductions) | 3 (3–3) | 3 (3–3) | 2 (2–2) | 3 (3–3) | 3 (3–3) | 3 (3–3) | 3 (3–3) |
35 (33–38) | 30 (28–31) | 18 (17–18) | 34 (33–34) | 34 (33–34) | 35 (35–36) | 33 (32–33) | |
Higher Vaccination coverage (Low/High rate of introductions) | 3 (3–3) | 2 (2–2) | 1 (1–1) | 3 (3–3) | 3 (3–3) | 3 (3–3) | 3 (3–3) |
36 (35–37) | 16 (16–17) | 11 (11–11) | 32 (31–33) | 32 (31–32) | 34 (34–35) | 30 (29–30) | |
Later date of intervention (Low/High rate of introductions) | 3 (3–4) | 2 (2–3) | 1 (1–1) | 3 (3–3) | 3 (3–3) | 3 (3–3) | 3 (3–3) |
52 (50–55) | 18 (17–18) | 12 (12–12) | 44 (42–46 ) | 43 (41–44) | 47 (46–49) | 41 (40–43) | |
Vaccine protects against disease only (Low/High rate of introductions) | 3 (3–3) | 2 (2–2) | 2 (2–2) | 3 (2–3) | 1 (1–2) | 3 (3–3) | 2 (2–2) |
36 (35–37) | 20 (20–21) | 21 (21–22) | 22 (22–23) | 20 (20–21) | 30 (30–31) | 14 (14–15) | |
Reduced introduction rate (by 1 order of magnitude) | 2 (2–2) | 1 (1–1) | 1 (1–1) | 2 (2–2) | 2 (2–2) | 2 (2–2) | 2 (2–2) |
6 (6–6) | 3 (3–3) | 2 (2–2) | 5 (5–5) | 5 (5–5) | 5 (5–6) | 5 (4–5) | |
Reduced introduction rate (by 2 orders of magnitude) | 2 (2–2) | 1 (1–1) | 1 (1–1) | 2 (2–2) | 2 (2–2) | 2 (2–2) | 2 (2–2) |
2 (2–2) | 1 (1–1) | 1 (1–1) | 2 (2–2) | 2 (2–2) | 2 (2–2) | 2 (2–2) |